Home The Word Brain	My Amedeo FAQ Privacy About
	Chinese Coaching Already know some Chinese? Stay on track with structured, one-on-one coaching to make steady, long-term progress. By Meng Wu and BSK.

Pulmonary Hypertension

Free Subscription Articles published in Eur Respir J Retrieve available abstracts of 156 articles: HTML format

Single Articles

December 2025
1. GRYNBLAT J, Farges M, Magro P, Savale L, et al
   Pulmonary hypertension in patients with Noonan syndrome.
   Eur Respir J. 2025 Dec 11:2501796. doi: 10.1183/13993003.01796-2025.
   PubMed     Abstract available
   
   
   November 2025
2. JEVNIKAR M, Brenot P, Kularatne M, Rodiere A, et al
   Chronic thromboembolic pulmonary hypertension associated with venous thoracic outlet syndrome: a retrospective case series.
   Eur Respir J. 2025 Nov 6:2501610. doi: 10.1183/13993003.01610-2025.
   PubMed    
   
   
   
3. OSORIO J, Tura-Ceide O, Pavia J, Vollmer I, et al
   Increased lung [(18)F]-FDG uptake in chronic thromboembolic pulmonary hypertension with distal involvement.
   Eur Respir J. 2025 Nov 6:2500130. doi: 10.1183/13993003.00130-2025.
   PubMed    
   
   
   
4. MESERVEY A, Feng R, Kawut SM, Moutchia J, et al
   Reply to: Enhancing methodological rigour in meta-analyses of renal dysfunction and outcomes in pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension.
   Eur Respir J. 2025;66:2501579.
   PubMed    
   
   
   
5. DONG F, Lin H, Han Y
   Enhancing methodological rigour in meta-analyses of renal dysfunction and outcomes in pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension.
   Eur Respir J. 2025;66:2501196.
   PubMed     Abstract available
   
   
   September 2025
6. KOVACS G, Zeder K, Olsson KM, Hoeper MM, et al
   Pulmonary vascular resistance to define severe pulmonary hypertension: cutting the Gordian knot.
   Eur Respir J. 2025;66:2501418.
   PubMed    
   
   
   
7. NAEIJE R, Chaouat A, Pinsky MR
   Reply to: Pulmonary vascular resistance to define severe pulmonary hypertension: cutting the Gordian knot.
   Eur Respir J. 2025;66:2501474.
   PubMed    
   
   
   
8. UYSAL OF, Hurst JR
   Pulmonary hypertension in COPD exacerbation: a transient storm with long-term consequences?
   Eur Respir J. 2025;66:2501508.
   PubMed    
   
   
   
9. RASTODER E, Sivapalan P, Hedsund C, Kamstrup P, et al
   Pulmonary pressure increases during acute exacerbation in COPD and clinical outcome.
   Eur Respir J. 2025;66:2500169.
   PubMed     Abstract available
   
   
   August 2025
10. HARBAUM L, Thenappan T
    Renal function dynamics in pulmonary hypertension trials: less than anticipated.
    Eur Respir J. 2025;66:2501042.
    PubMed    
    
    
    
11. SITBON O, Boucly A, Weatherald J, Antigny F, et al
    Drugs targeting novel pathways in pulmonary arterial hypertension.
    Eur Respir J. 2025;66:2401830.
    PubMed     Abstract available
    
    
    
12. BACCELLI A, Rinaldo RF, Haji G, Davies RJ, et al
    Prognostic value of cardiopulmonary exercise testing in pulmonary arterial hypertension.
    Eur Respir J. 2025;66:2402026.
    PubMed     Abstract available
    
    
    July 2025
13. LANG IM
    A reason to celebrate: multimodal treatments and recent improvements in the long-term outcomes of patients with chronic thromboembolic pulmonary hypertension.
    Eur Respir J. 2025;66:2500562.
    PubMed    
    
    
    
14. PRESTON IR, Badesch D, Ghofrani HA, Gibbs JSR, et al
    A long-term follow-up study of sotatercept for treatment of pulmonary arterial hypertension: interim results of SOTERIA.
    Eur Respir J. 2025;66:2401435.
    PubMed     Abstract available
    
    
    June 2025
15. NAEIJE R, Chaouat A, Pinsky MR
    Viewpoint: a critique of pulmonary vascular resistance to define severe pulmonary hypertension.
    Eur Respir J. 2025;65:2500409.
    PubMed    
    
    
    May 2025
16. MESERVEY A, Al-Naamani N, Minhas J, Fritz JS, et al
    Renal dysfunction and outcomes in pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension: an individual participant data meta-analysis.
    Eur Respir J. 2025 May 22:2402400. doi: 10.1183/13993003.02400-2024.
    PubMed     Abstract available
    
    
    
17. BALMAIN BN, Babb TG
    Reply to: Unravelling the physiology of exercise pulmonary hypertension in patients with heart failure with preserved ejection fraction.
    Eur Respir J. 2025;65:2500543.
    PubMed    
    
    
    
18. JHA AK
    Unravelling the physiology of exercise pulmonary hypertension in patients with heart failure with preserved ejection fraction.
    Eur Respir J. 2025;65:2500384.
    PubMed    
    
    
    
19. BOUCLY A, Montani D, Bauer F, Artaud-Macari E, et al
    Initial therapy in patients with pulmonary arterial hypertension and cardiovascular comorbidities.
    Eur Respir J. 2025;65:2400895.
    PubMed     Abstract available
    
    
    
20. HOEPER MM, Gomberg-Maitland M, Badesch DB, Gibbs JSR, et al
    Efficacy and safety of the activin signalling inhibitor, sotatercept, in a pooled analysis of PULSAR and STELLAR studies.
    Eur Respir J. 2025;65:2401424.
    PubMed     Abstract available
    
    
    
21. SELMAN M, Buendia-Roldan I, Pardo A
    Decoding the complexity: mechanistic insights into comorbidities in idiopathic pulmonary fibrosis.
    Eur Respir J. 2025;65:2402418.
    PubMed     Abstract available
    
    
    March 2025
22. KIKO T, Asano R, Yoshikawa Y, Endo H, et al
    Survival trends in patients with chronic thromboembolic pulmonary hypertension: An observational study.
    Eur Respir J. 2025 Mar 6:2402268. doi: 10.1183/13993003.02268-2024.
    PubMed     Abstract available
    
    
    
23. AUSTIN ED
    X-linked filaminopathy: another pulmonary hypertension syndrome.
    Eur Respir J. 2025;65:2500073.
    PubMed    
    
    
    
24. LILEY J, Bunclark K, Newnham M, Cannon J, et al
    Development of an open-source tool for risk assessment in pulmonary endarterectomy.
    Eur Respir J. 2025;65:2401001.
    PubMed     Abstract available
    
    
    January 2025
25. ALENEZI F, Costelle A, Sharma P, Barrett M, et al
    (129)Xenon MR Imaging and Spectroscopy Detects Response to Therapy in Pulmonary Hypertension.
    Eur Respir J. 2025 Jan 30:2401651. doi: 10.1183/13993003.01651-2024.
    PubMed    
    
    
    
26. WRIGHT SP, Karvasarki E, Buchan TA, Gurtu V, et al
    Contemporary pulmonary hypertension hemodynamic definitions stratify mortality risk in candidates for advanced heart failure therapies.
    Eur Respir J. 2025 Jan 30:2401640. doi: 10.1183/13993003.01640-2024.
    PubMed    
    
    
    December 2024
27. 
    "Targeting transforming growth factor-beta receptors in pulmonary hypertension." Christophe Guignabert and Marc Humbert. Eur Respir J 2021; 57: 2002341.
    Eur Respir J. 2024;64:2052341.
    PubMed    
    
    
    November 2024
28. KOVACS G, Humbert M, Avian A, Lewis GD, et al
    Prognostic relevance of Exercise Pulmonary Hypertension: Results of the multi-center PEX-NET Clinical Research Collaboration.
    Eur Respir J. 2024 Nov 27:2400698. doi: 10.1183/13993003.00698-2024.
    PubMed     Abstract available
    
    
    
29. HEUTS S, Kawczynski MJ, Leus A, Godinas L, et al
    The volume-outcome relation for pulmonary endarterectomy in chronic thrombo-embolic pulmonary hypertension.
    Eur Respir J. 2024 Nov 21:2401865. doi: 10.1183/13993003.01865-2024.
    PubMed     Abstract available
    
    
    
30. STOURM L, Grynblat J, Savale L, Lacoste-Palasset T, et al
    Pulmonary hypertension in patients carrying FLNA loss-of-function variants.
    Eur Respir J. 2024 Nov 7:2401132. doi: 10.1183/13993003.01132-2024.
    PubMed     Abstract available
    
    
    
31. BALMAIN BN, Tomlinson AR, Goh JT, MacNamara JP, et al
    Pulmonary gas exchange in relation to exercise pulmonary hypertension in patients with heart failure with preserved ejection fraction.
    Eur Respir J. 2024 Nov 7:2400722. doi: 10.1183/13993003.00722-2024.
    PubMed     Abstract available
    
    
    
32. DE JESUS PEREZ VA, Lai YC
    TAZ and RUNX2 awareness in pulmonary hypertension due to left heart disease.
    Eur Respir J. 2024;64:2400905.
    PubMed    
    
    
    
33. LIU SF, Kucherenko MM, Sang P, Li Q, et al
    RUNX2 is stabilised by TAZ and drives pulmonary artery calcification and lung vascular remodelling in pulmonary hypertension due to left heart disease.
    Eur Respir J. 2024;64:2300844.
    PubMed     Abstract available
    
    
    
34. 
    "Chronic thromboembolic pulmonary hypertension is an uncommon complication of COVID-19: UK national surveillance and observational screening cohort studies." S.A. Reddy, J. Newman, O.C. Leavy, et al. Eur Respir J 2024; 64: 2301742.
    Eur Respir J. 2024;64:2351742.
    PubMed    
    
    
    
35. HUMBERT M, Hassoun PM, Chin KM, Bortman G, et al
    MK-5475, an inhaled soluble guanylate cyclase stimulator, for treatment of pulmonary arterial hypertension: the INSIGNIA-PAH study.
    Eur Respir J. 2024;64:2401110.
    PubMed     Abstract available
    
    
    October 2024
36. KIM NH, Channick R, Delcroix M, Madani M, et al
    Efficacy and safety of selexipag in patients with inoperable or persistent/recurrent CTEPH (SELECT randomised trial).
    Eur Respir J. 2024;64:2400193.
    PubMed     Abstract available
    
    
    
37. TOTH EN, Celant LR, Niglas M, Jansen S, et al
    Deep phenotyping of unaffected carriers of pathogenic BMPR2 variants screened for pulmonary arterial hypertension.
    Eur Respir J. 2024;64:2400442.
    PubMed     Abstract available
    
    
    
38. PRICE LC, Lyon A, Boyd K
    Reversible carfilzomib-induced pulmonary arterial hypertension: don't take your eyes off the ball!
    Eur Respir J. 2024;64:2401087.
    PubMed    
    
    
    
39. DE BIE EMDD, Toshner M
    What to do when pulmonary arterial hypertension screening suggests neither fish nor fowl? The DOLPHIN-GENESIS study.
    Eur Respir J. 2024;64:2401369.
    PubMed    
    
    
    
40. 
    ERJ Podcast October 2024: World Symposium on Pulmonary Hypertension.
    Eur Respir J. 2024;64:24E6404.
    PubMed    
    
    
    
41. HEMNES AR, Celermajer DS, D'Alto M, Haddad F, et al
    Pathophysiology of the right ventricle and its pulmonary vascular interaction.
    Eur Respir J. 2024;64:2401321.
    PubMed     Abstract available
    
    
    
42. RAJAGOPAL S, Bogaard HJ, Elbaz MSM, Freed BH, et al
    Emerging multimodality imaging techniques for the pulmonary circulation.
    Eur Respir J. 2024;64:2401128.
    PubMed     Abstract available
    
    
    
43. CHIN KM, Gaine SP, Gerges C, Jing ZC, et al
    Treatment algorithm for pulmonary arterial hypertension.
    Eur Respir J. 2024;64:2401325.
    PubMed     Abstract available
    
    
    
44. KIM NH, D'Armini AM, Delcroix M, Jais X, et al
    Chronic thromboembolic pulmonary disease.
    Eur Respir J. 2024;64:2401294.
    PubMed     Abstract available
    
    
    
45. DARDI F, Boucly A, Benza R, Frantz R, et al
    Risk stratification and treatment goals in pulmonary arterial hypertension.
    Eur Respir J. 2024;64:2401323.
    PubMed     Abstract available
    
    
    
46. WEATHERALD J, Fleming TR, Wilkins MR, Cascino TM, et al
    Clinical trial design, end-points, and emerging therapies in pulmonary arterial hypertension.
    Eur Respir J. 2024;64:2401205.
    PubMed     Abstract available
    
    
    September 2024
47. SAHAY S, Benza RL
    The evolution of the European risk stratification system for pulmonary arterial hypertension.
    Eur Respir J. 2024;64:2400943.
    PubMed    
    
    
    
48. BOUCLY A, Beurnier A, Turquier S, Jevnikar M, et al
    Risk stratification refinements with inclusion of haemodynamic variables at follow-up in patients with pulmonary arterial hypertension.
    Eur Respir J. 2024;64:2400197.
    PubMed     Abstract available
    
    
    August 2024
49. HUMBERT M, Galie N, Rubin LJ, Simonneau G, et al
    The Seventh World Symposium on Pulmonary Hypertension: our journey to Barcelona.
    Eur Respir J. 2024 Aug 30:2401222. doi: 10.1183/13993003.01222-2024.
    PubMed    
    
    
    
50. IVY D, Rosenzweig EB, Abman SH, Beghetti M, et al
    Embracing the challenges of neonatal and paediatric pulmonary hypertension.
    Eur Respir J. 2024 Aug 29:2401345. doi: 10.1183/13993003.01345-2024.
    PubMed     Abstract available
    
    
    
51. AUSTIN ED, Aldred MA, Alotaibi M, Graf S, et al
    Genetics and precision genomics approaches to pulmonary hypertension.
    Eur Respir J. 2024 Aug 29:2401370. doi: 10.1183/13993003.01370-2024.
    PubMed     Abstract available
    
    
    
52. FORD HJ, Brunetti C, Ferrari P, Meszaros G, et al
    Exploring the patient perspective in pulmonary hypertension.
    Eur Respir J. 2024 Aug 29:2401129. doi: 10.1183/13993003.01129-2024.
    PubMed     Abstract available
    
    
    
53. MARON BA, Bortman G, De Marco T, Huston JH, et al
    Pulmonary hypertension associated with left heart disease.
    Eur Respir J. 2024 Aug 29:2401344. doi: 10.1183/13993003.01344-2024.
    PubMed     Abstract available
    
    
    
54. PRESTON IR, Howard LS, Langleben D, Lichtblau M, et al
    Management of pulmonary hypertension in special conditions.
    Eur Respir J. 2024 Aug 29:2401180. doi: 10.1183/13993003.01180-2024.
    PubMed     Abstract available
    
    
    
55. KOVACS G, Bartolome S, Denton CP, Gatzoulis MA, et al
    Definition, classification and diagnosis of pulmonary hypertension.
    Eur Respir J. 2024 Aug 29:2401324. doi: 10.1183/13993003.01324-2024.
    PubMed     Abstract available
    
    
    
56. GUIGNABERT C, Aman J, Bonnet S, Dorfmuller P, et al
    Pathology and pathobiology of pulmonary hypertension: current insights and future directions.
    Eur Respir J. 2024 Aug 29:2401095. doi: 10.1183/13993003.01095-2024.
    PubMed     Abstract available
    
    
    
57. SAVALE L, Benazzo A, Corris P, Keshavjee S, et al
    Transplantation, bridging, and support technologies in pulmonary hypertension.
    Eur Respir J. 2024 Aug 29:2401193. doi: 10.1183/13993003.01193-2024.
    PubMed     Abstract available
    
    
    
58. SHLOBIN OA, Adir Y, Barbera JA, Cottin V, et al
    Pulmonary hypertension associated with lung diseases.
    Eur Respir J. 2024 Aug 29:2401200. doi: 10.1183/13993003.01200-2024.
    PubMed     Abstract available
    
    
    
59. VARGHESE NP, Austin ED, Galambos C, Mullen MP, et al
    An Interdisciplinary Consensus Approach to Pulmonary Hypertension in Developmental Lung Disorders.
    Eur Respir J. 2024 Aug 15:2400639. doi: 10.1183/13993003.00639-2024.
    PubMed     Abstract available
    
    
    
60. ZEDER K, Avian A, Mak S, Giannakoulas G, et al
    Pulmonary arterial wedge pressure in healthy subjects: a meta-analysis.
    Eur Respir J. 2024;64:2400967.
    PubMed    
    
    
    
61. FARMAKIS IT, Konstantinides SV
    COVID-19 changed the world - without changing CTEPH.
    Eur Respir J. 2024;64:2401467.
    PubMed    
    
    
    
62. REDDY SA, Newman J, Leavy OC, Ghani H, et al
    Chronic thromboembolic pulmonary hypertension is an uncommon complication of COVID-19: UK national surveillance and observational screening cohort studies.
    Eur Respir J. 2024;64:2301742.
    PubMed     Abstract available
    
    
    July 2024
63. WEATHERALD J, Hemnes AR, Maron BA, Mielniczuk LM, et al
    Phenotypes in Pulmonary Hypertension.
    Eur Respir J. 2024 Jul 4:2301633. doi: 10.1183/13993003.01633-2023.
    PubMed     Abstract available
    
    
    
64. PLUNKETT MJ, Sayegh ALC, McWilliams TJ, Sithamparanathan S, et al
    The effects of peripheral chemoreflex suppression on ventilatory efficiency and exercise duration in pulmonary arterial hypertension.
    Eur Respir J. 2024;64:2400307.
    PubMed    
    
    
    
65. OLSSON KM, Fuge J, Park DH, Kamp JC, et al
    Right heart function during and after pregnancy in women with pulmonary arterial hypertension.
    Eur Respir J. 2024;64:2400179.
    PubMed     Abstract available
    
    
    
66. PATTERSON MT, Prins KW
    An exercise in relaxation: right ventricular diastolic function predicts exercise capacity in pulmonary arterial hypertension.
    Eur Respir J. 2024;64:2401142.
    PubMed    
    
    
    
67. CUBERO SALAZAR IM, Lancaster AC, Jani VP, Montovano MJ, et al
    Poor cardiac output reserve in pulmonary arterial hypertension is associated with right ventricular stiffness and impaired interventricular dependence.
    Eur Respir J. 2024;64:2400420.
    PubMed     Abstract available
    
    
    
68. CASSADY SJ, Maron BA
    Artificial intelligence meets pulmonary hypertension: early detection for a late-presenting disease.
    Eur Respir J. 2024;64:2401138.
    PubMed    
    
    
    June 2024
69. LUIJTEN D, Valerio L, Boon GJAM, Barco S, et al
    Optimisation of detecting chronic thromboembolic pulmonary hypertension in acute pulmonary embolism survivors: the InShape IV study.
    Eur Respir J. 2024 Jun 27:2400544. doi: 10.1183/13993003.00544-2024.
    PubMed     Abstract available
    
    
    
70. DUBROCK HM, Wagner TE, Carlson K, Carpenter CL, et al
    An electrocardiogram-based AI algorithm for early detection of pulmonary hypertension.
    Eur Respir J. 2024 Jun 27:2400192. doi: 10.1183/13993003.00192-2024.
    PubMed     Abstract available
    
    
    
71. KOVACS G, Humbert M
    Primum non nocere, secundum cavere, tertium sanare: lessons on the management of pulmonary hypertension associated with COPD.
    Eur Respir J. 2024;63:2400765.
    PubMed    
    
    
    
72. THENAPPAN T
    Impact of tricuspid regurgitation on right ventricular function and clinical outcomes in pulmonary arterial hypertension: food for thought.
    Eur Respir J. 2024;63:2400797.
    PubMed    
    
    
    
73. YOSHIDA K, van Wezenbeek J, Wessels JN, de Man FS, et al
    Tricuspid regurgitation in pulmonary arterial hypertension: a right ventricular volumetric and functional analysis.
    Eur Respir J. 2024;63:2301696.
    PubMed     Abstract available
    
    
    
74. BUDHRAM B, Zamanian RT, Weatherald J
    Moving the needle on proteasome inhibitor-induced pulmonary arterial hypertension: a definite maybe.
    Eur Respir J. 2024;63:2400946.
    PubMed    
    
    
    May 2024
75. NATHAN SD, Argula R, Trivieri MG, Aziz S, et al
    Inhaled Treprostinil in Pulmonary Hypertension Associated with COPD: PERFECT study results.
    Eur Respir J. 2024 May 29:2400172. doi: 10.1183/13993003.00172-2024.
    PubMed     Abstract available
    
    
    
76. CAMPEDELLI L, Nouraie SM, Risbano MG
    Non-arterial line cardiac output calculation misclassifies exercise pulmonary hypertension and increases risk of data loss particularly in black, Scleroderma, and Raynaud's patients during invasive exercise testing.
    Eur Respir J. 2024 May 23:2302232. doi: 10.1183/13993003.02232-2023.
    PubMed     Abstract available
    
    
    
77. GRYNBLAT J, Khouri C, Hlavaty A, Jais X, et al
    Characteristics and outcomes of patients developing pulmonary hypertension associated with proteasome inhibitors.
    Eur Respir J. 2024 May 2:2302158. doi: 10.1183/13993003.02158-2023.
    PubMed     Abstract available
    
    
    
78. MA JL, Wang AY, Lu D, Cheng CY, et al
    The puzzles surrounding the impact of face masks on 6-minute walking distance in pulmonary hypertension.
    Eur Respir J. 2024;63:2301879.
    PubMed    
    
    
    
79. WISSMULLER M, Wartner V, Hohmann C, Adler J, et al
    Reply to: The puzzles surrounding the impact of face masks on 6-minute walking distance in pulmonary hypertension.
    Eur Respir J. 2024;63:2400529.
    PubMed    
    
    
    
80. VALDEOLMILLOS E, Foray C, Albenque G, Batteux C, et al
    Percutaneous atrial septal defect closure in patients with pulmonary arterial hypertension.
    Eur Respir J. 2024;63:2301649.
    PubMed    
    
    
    April 2024
81. AGARWAL S, Fineman J, Cornfield DN, Alvira CM, et al
    VIEWING PULMONARY HYPERTENSION THROUGH A PEDIATRIC LENS.
    Eur Respir J. 2024 Apr 4:2301518. doi: 10.1183/13993003.01518-2023.
    PubMed    
    
    
    
82. GRYNBLAT J, Bogaard HJ, Eyries M, Meyrignac O, et al
    Pulmonary vascular phenotype identified in patients with GDF2 (BMP9) or BMP10 variants: an international multicentre study.
    Eur Respir J. 2024;63:2301634.
    PubMed     Abstract available
    
    
    
83. WOOLF B, Perry JA, Hong CC, Wilkins MR, et al
    Multi-biobank summary data Mendelian randomisation does not support a causal effect of IL-6 signalling on risk of pulmonary arterial hypertension.
    Eur Respir J. 2024;63:2302031.
    PubMed     Abstract available
    
    
    
84. SANGES S, Tian W, Dubucquoi S, Chang JL, et al
    B-cells in pulmonary arterial hypertension: friend, foe or bystander?
    Eur Respir J. 2024;63:2301949.
    PubMed     Abstract available
    
    
    March 2024
85. NAEIJE R
    High altitude travelling with pulmonary arterial hypertension.
    Eur Respir J. 2024;63:2400111.
    PubMed    
    
    
    
86. HOWARD LS, Price LC
    Systematic pulmonary embolism follow-up: why we should all do it!
    Eur Respir J. 2024;63:2400253.
    PubMed    
    
    
    February 2024
87. MULLER J, Titz A, Schneider SR, Bauer M, et al
    The effect of high altitude (2500 m) on incremental cycling exercise in patients with pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension: a randomised controlled cross-over trial.
    Eur Respir J. 2024 Feb 29:2301001. doi: 10.1183/13993003.01001-2023.
    PubMed     Abstract available
    
    
    
88. GERGES C, Montani D, Humbert M, Lang IM, et al
    Hemodynamic phenotypes of pulmonary hypertension associated with left heart disease: a moving target.
    Eur Respir J. 2024 Feb 15:2302280. doi: 10.1183/13993003.02280-2023.
    PubMed    
    
    
    
89. DURRINGTON C, Hurdman JA, Elliot CA, Maclean R, et al
    Systematic pulmonary embolism follow-up increases diagnostic rates of chronic thromboembolic pulmonary hypertension and identifies less severe disease: results from the ASPIRE Registry.
    Eur Respir J. 2024 Feb 1:2300846. doi: 10.1183/13993003.00846-2023.
    PubMed     Abstract available
    
    
    January 2024
90. PLUNKETT MJ, Sayegh ALC, McWilliams TJ, Sithamparanathan S, et al
    The skeletal muscle metaboreflex: a novel driver of ventilation, dyspnoea and pulmonary haemodynamics during exercise in pulmonary arterial hypertension.
    Eur Respir J. 2024;63:2300952.
    PubMed     Abstract available
    
    
    December 2023
91. TAMURA Y, Tamura Y, Shigeta A, Hosokawa K, et al
    Adult-onset idiopathic peripheral pulmonary artery stenosis.
    Eur Respir J. 2023;62:2300763.
    PubMed     Abstract available
    
    
    November 2023
92. HUMBERT M
    Viewpoint: activin signalling inhibitors for the treatment of pulmonary arterial hypertension.
    Eur Respir J. 2023;62:2301726.
    PubMed    
    
    
    
93. NEPTUNE ER, Cardoso WV
    Unravelling the expanding role of FGF10 signalling in lung homeostasis and maintenance.
    Eur Respir J. 2023;62:2301691.
    PubMed    
    
    
    
94. PAUSCH C, Pittrow D, Hoeper MM, Huscher D, et al
    Performance of the ESC/ERS 4-strata risk stratification model for pulmonary arterial hypertension with missing variables.
    Eur Respir J. 2023;62:2301023.
    PubMed     Abstract available
    
    
    October 2023
95. HADZIC S, Wu CY, Gredic M, Pak O, et al
    Fibroblast growth factor 10 reverses cigarette smoke- and elastase-induced emphysema and pulmonary hypertension in mice.
    Eur Respir J. 2023 Oct 26:2201606. doi: 10.1183/13993003.01606-2022.
    PubMed     Abstract available
    
    
    
96. WISSMULLER M, Wartner V, Hohmann C, Adler J, et al
    Impact of Face Masks on the Six Minute Walking Distance in Pulmonary Hypertension Patients During the COVID-19 Pandemic: A Prospective, Randomised Cross-over Study.
    Eur Respir J. 2023 Oct 12:2201454. doi: 10.1183/13993003.01454-2022.
    PubMed    
    
    
    
97. JEVNIKAR M, Solinas S, Brenot P, Lechartier B, et al
    Sequential multimodal therapy in chronic thromboembolic pulmonary hypertension (CTEPH) with mixed anatomical lesions: a proof of concept.
    Eur Respir J. 2023 Oct 6:2300517. doi: 10.1183/13993003.00517-2023.
    PubMed    
    
    
    
98. MCNEILL JN, Roshandelpoor A, Alotaibi M, Choudhary A, et al
    The association of eicosanoids and eicosanoid-related metabolites with pulmonary hypertension.
    Eur Respir J. 2023;62:2300561.
    PubMed     Abstract available
    
    
    
99. ANDRUSKA AM, Zamanian RT
    Sorting the wheat from the chaff: the innovative case of precision transpulmonary metabolomics.
    Eur Respir J. 2023;62:2301547.
    PubMed    
    
    
    September 2023
100. HAFNER F, Kindt A, Strobl K, Forster K, et al
     MRI pulmonary artery flow detects lung vascular pathology in preterms with lung disease.
     Eur Respir J. 2023 Sep 7:2202445. doi: 10.1183/13993003.02445-2022.
     PubMed     Abstract available
     
     
     
101. PRICE LC, McCabe C, Weatherald J
     Reducing the pressure in pulmonary arterial hypertension: sotatercept, haemodynamics and the right ventricle.
     Eur Respir J. 2023;62:2301513.
     PubMed    
     
     
     
102. SOUZA R, Badesch DB, Ghofrani HA, Gibbs JSR, et al
     Effects of sotatercept on haemodynamics and right heart function: analysis of the STELLAR trial.
     Eur Respir J. 2023;62:2301107.
     PubMed     Abstract available
     
     
     August 2023
103. OLSSON KM, Fuge J, Park DH, Kamp JC, et al
     Effects of sotatercept on lung diffusion capacity and blood gases in patients with pulmonary arterial hypertension.
     Eur Respir J. 2023;62:2301070.
     PubMed    
     
     
     
104. ALABED S, Garg P, Alandejani F, Dwivedi K, et al
     Establishing minimally important differences for cardiac MRI end-points in pulmonary arterial hypertension.
     Eur Respir J. 2023;62:2202225.
     PubMed     Abstract available
     
     
     July 2023
105. PICCARI L, Blanco I, Torralba Y, Arismendi E, et al
     Mechanisms of hypoxaemia in severe pulmonary hypertension associated with COPD.
     Eur Respir J. 2023 Jul 6:2300463. doi: 10.1183/13993003.00463-2023.
     PubMed    
     
     
     
106. YEH FC, Chen CN, Xie CY, Baxan N, et al
     TLR7/8 activation induces autoimmune vasculopathy and causes severe pulmonary arterial hypertension.
     Eur Respir J. 2023;62:2300204.
     PubMed     Abstract available
     
     
     
107. PAN HM, McClelland RL, Moutchia J, Appleby DH, et al
     Heterogeneity of treatment effects by risk in pulmonary arterial hypertension.
     Eur Respir J. 2023;62:2300190.
     PubMed     Abstract available
     
     
     June 2023
108. LUIJTEN D, Talerico R, Barco S, Cannegieter SC, et al
     Incidence of chronic thromboembolic pulmonary hypertension after acute pulmonary embolism: an updated systematic review and meta-analysis.
     Eur Respir J. 2023 Jun 15:2300449. doi: 10.1183/13993003.00449-2023.
     PubMed    
     
     
     
109. GONCHAROVA EA, Kudryashova TV, Pullamsetti SS
     Too hot? Too cold? Wnt signalling in pulmonary arterial hypertension: can we treat it "just right"?
     Eur Respir J. 2023;61:2300504.
     PubMed    
     
     
     
110. CHAKRABORTY A, Nathan A, Orcholski M, Agarwal S, et al
     Wnt7a deficit is associated with dysfunctional angiogenesis in pulmonary arterial hypertension.
     Eur Respir J. 2023;61:2201625.
     PubMed     Abstract available
     
     
     
111. COTTIN V, Valenzuela C, Humbert M
     Inhaled treprostinil for interstitial lung disease-associated pulmonary hypertension: a silver lining on a very dark cloud.
     Eur Respir J. 2023;61:2300944.
     PubMed    
     
     
     
112. WAXMAN A, Restrepo-Jaramillo R, Thenappan T, Engel P, et al
     Long-term inhaled treprostinil for pulmonary hypertension due to interstitial lung disease: INCREASE open-label extension study.
     Eur Respir J. 2023;61:2202414.
     PubMed     Abstract available
     
     
     May 2023
113. DE MAN FS, Vonk Noordegraaf A
     The right ventricle tamed.
     Eur Respir J. 2023;61:2300509.
     PubMed    
     
     
     
114. SAMARANAYAKE CB, Kempny A, Naeije R, Gatzoulis M, et al
     Beta-blockade improves right ventricular diastolic function in exercising pulmonary arterial hypertension.
     Eur Respir J. 2023;61:2300144.
     PubMed     Abstract available
     
     
     April 2023
115. DE JONG CMM, Visser C, Bemelmans RHH, Boersma WG, et al
     Chronic thromboembolic pulmonary hypertension and clot resolution after COVID-19-associated pulmonary embolism.
     Eur Respir J. 2023;61:2300171.
     PubMed    
     
     
     
116. SCHMIDT KH, Milger K, Pausch C, Huscher D, et al
     Trends in COVID-19-associated mortality in patients with pulmonary hypertension: a COMPERA analysis.
     Eur Respir J. 2023;61:2202440.
     PubMed     Abstract available
     
     
     March 2023
117. KOUDSTAAL T, Boomars KA
     Inflammatory biomarkers in pulmonary arterial hypertension: ready for clinical implementation?
     Eur Respir J. 2023;61:2300018.
     PubMed    
     
     
     
118. BOUCLY A, Tu L, Guignabert C, Rhodes C, et al
     Cytokines as prognostic biomarkers in pulmonary arterial hypertension.
     Eur Respir J. 2023;61:2201232.
     PubMed     Abstract available
     
     
     February 2023
119. EICHSTAEDT CA, Belge C, Chung WK, Graf S, et al
     Genetic counselling and testing in pulmonary arterial hypertension: a consensus statement on behalf of the International Consortium for Genetic Studies in PAH.
     Eur Respir J. 2023;61:2201471.
     PubMed     Abstract available
     
     
     January 2023
120. RUBIN LJ, Naeije R
     Sotatercept for pulmonary arterial hypertension: something old and something new.
     Eur Respir J. 2023;61:2201972.
     PubMed    
     
     
     
121. PRICE LC, Weatherald J
     The new 2022 pulmonary hypertension guidelines: some small steps and some giant leaps forward for evidence-based care.
     Eur Respir J. 2023;61:2202150.
     PubMed    
     
     
     
122. HUMBERT M, McLaughlin V, Gibbs JSR, Gomberg-Maitland M, et al
     Sotatercept for the treatment of pulmonary arterial hypertension: PULSAR open-label extension.
     Eur Respir J. 2023;61:2201347.
     PubMed     Abstract available
     
     
     December 2022
123. GALKIN A, Sitapara R, Clemons B, Garcia E, et al
     Inhaled seralutinib exhibits potent efficacy in models of pulmonary arterial hypertension.
     Eur Respir J. 2022;60:2102356.
     PubMed     Abstract available
     
     
     
124. ORMISTON ML, Jankov RP, Stewart DJ
     Oh NO! Loss of PHD2 leads to "radical" changes in the lung vasculature.
     Eur Respir J. 2022;60:2201776.
     PubMed    
     
     
     November 2022
125. SHU T, Zhang J, Zhou Y, Chen Z, et al
     Eosinophils Protect Against Pulmonary Hypertension through 14-HDHA and 17-HDHA.
     Eur Respir J. 2022 Nov 24:2200582. doi: 10.1183/13993003.00582-2022.
     PubMed     Abstract available
     
     
     October 2022
126. MICKAEL C, Lee MH, Graham BB
     The COVID-19 pandemic and pulmonary arterial hypertension in Italy: adaptation, outcomes and valuable lessons learned.
     Eur Respir J. 2022;60.
     PubMed    
     
     
     
127. BADAGLIACCA R, Papa S, D'Alto M, Ghio S, et al
     The paradox of pulmonary arterial hypertension in Italy in the COVID-19 era: is risk of disease progression around the corner?
     Eur Respir J. 2022;60.
     PubMed     Abstract available
     
     
     
128. ADNOT S, Lipskaia L, Bischof O
     What is hidden behind a pulmonary hypertensive, fibrotic and inflammatory phenotype?
     Eur Respir J. 2022;60.
     PubMed    
     
     
     September 2022
129. RIOU M, Canuet M, Ghigna MR, Eyries M, et al
     First histological description of pulmonary and vascular abnormalities of pulmonary hypertension associated with KDR pathogenic variant.
     Eur Respir J. 2022 Sep 30. pii: 13993003.01197-2022.
     PubMed    
     
     
     
130. HASSAN HJ, Naranjo M, Kazzi B, Housten-Harris T, et al
     Risk assessment of systemic sclerosis-associated pulmonary arterial hypertension: cardiac index versus stroke volume index.
     Eur Respir J. 2022;60.
     PubMed    
     
     
     
131. DOUSCHAN P, Tello K, Rieth AJ, Wiedenroth CB, et al
     Right ventricular-pulmonary arterial coupling and its relationship to exercise haemodynamics in a continuum of patients with pulmonary vascular disease due to chronic thromboembolism.
     Eur Respir J. 2022;60.
     PubMed    
     
     
     August 2022
132. HUMBERT M, Kovacs G, Hoeper MM, Badagliacca R, et al
     2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension.
     Eur Respir J. 2022 Aug 25. pii: 13993003.00879-2022.
     PubMed    
     
     
     
133. VAN DE VEERDONK MC, Vonk-Noordegraaf A, Vachiery JL
     Unbowed, unbent, unbroken: predicting pulmonary hypertension using echocardiography.
     Eur Respir J. 2022;60.
     PubMed    
     
     
     
134. LECHARTIER B, Girerd B, Eyries M, Beurnier A, et al
     Screening for pulmonary veno-occlusive disease in heterozygous EIF2AK4 variant carriers.
     Eur Respir J. 2022;60.
     PubMed    
     
     
     
135. RAI N, Sydykov A, Kojonazarov B, Wilhelm J, et al
     Targeting peptidyl-prolyl isomerase 1 in experimental pulmonary arterial hypertension.
     Eur Respir J. 2022;60.
     PubMed     Abstract available
     
     
     July 2022
136. MADOUN S, Piliero N, Guillien A, Salvat M, et al
     Improved ventilatory efficiency to evidence haemodynamic improvement after balloon pulmonary angioplasty in chronic thromboembolic pulmonary hypertension.
     Eur Respir J. 2022 Jul 27. pii: 13993003.00762-2022.
     PubMed    
     
     
     
137. LIU B, Peng Y, Yi D, Machireddy N, et al
     Endothelial PHD2 deficiency induces nitrative stress via suppression of caveolin-1 in pulmonary hypertension.
     Eur Respir J. 2022 Jul 7. pii: 13993003.02643-2021.
     PubMed     Abstract available
     
     
     
138. STUBBS H, Lua S, Brewis M, Johnson M, et al
     COMPERA 2.0 risk stratification in medically-managed chronic thromboembolic pulmonary hypertension.
     Eur Respir J. 2022 Jul 7. pii: 13993003.00313-2022.
     PubMed    
     
     
     
139. GHOFRANI HA
     Selexipag for inoperable CTEPH: why meeting a primary endpoint simply isn't enough.
     Eur Respir J. 2022;60.
     PubMed    
     
     
     
140. DU M, Jiang H, Liu H, Zhao X, et al
     Single-cell RNA sequencing reveals that BMPR2 mutation regulates right ventricular function via ID genes.
     Eur Respir J. 2022;60.
     PubMed     Abstract available
     
     
     
141. HOEPER MM, Pausch C, Olsson KM, Huscher D, et al
     COMPERA 2.0: a refined four-stratum risk assessment model for pulmonary arterial hypertension.
     Eur Respir J. 2022;60.
     PubMed     Abstract available
     
     
     
142. SWINNEN K, Bijnens E, Casas L, Nawrot TS, et al
     Health effects of exposure to residential air pollution in patients with pulmonary arterial hypertension: a cohort study in Belgium.
     Eur Respir J. 2022;60.
     PubMed    
     
     
     June 2022
143. CERTAIN MC, Baron A, Turpin M, Ebstein N, et al
     Outcomes of cirrhotic patients with pre-capillary pulmonary hypertension and pulmonary vascular resistance between 2 and 3 Wood Units.
     Eur Respir J. 2022 Jun 9. pii: 13993003.00107-2022.
     PubMed    
     
     
     
144. ALI MK, Schimmel K, Zhao L, Chen CK, et al
     The role of circular RNAs in pulmonary hypertension.
     Eur Respir J. 2022 Jun 9. pii: 13993003.00012-2022.
     PubMed     Abstract available
     
     
     
145. BOUCLY A, Humbert M, Sitbon O
     To be or not to be... treated with initial combination therapy, that is the (PAH) question.
     Eur Respir J. 2022;59.
     PubMed    
     
     
     
146. HOEPER MM, Pausch C, Grunig E, Staehler G, et al
     Temporal trends in pulmonary arterial hypertension: results from the COMPERA registry.
     Eur Respir J. 2022;59.
     PubMed     Abstract available
     
     
     
147. ZELT JGE, Sugarman J, Weatherald J, Partridge ACR, et al
     Mortality trends in pulmonary arterial hypertension in Canada: a temporal analysis of survival per ESC/ERS guideline era.
     Eur Respir J. 2022;59.
     PubMed     Abstract available
     
     
     
148. VAN DER HAVE O, Westoo C, Ahrne F, Tian X, et al
     Shunt-type plexiform lesions identified in the Sugen5416/hypoxia rat model of pulmonary arterial hypertension using synchrotron-based phase-contrast micro-CT.
     Eur Respir J. 2022;59.
     PubMed    
     
     
     
149. NAEIJE R, Richter MJ, Rubin LJ
     The physiological basis of pulmonary arterial hypertension.
     Eur Respir J. 2022;59.
     PubMed     Abstract available
     
     
     
150. WESSELS JN, Mouratoglou SA, van Wezenbeek J, Handoko ML, et al
     Right atrial function is associated with right venticular diastolic stiffness: RA-RV interaction in pulmonary arterial hypertension.
     Eur Respir J. 2022;59.
     PubMed     Abstract available
     
     
     
151. JUTANT EM, Tu L, Thuillet R, Picard V, et al
     Erythrocytes are altered in pulmonary arterial hypertension.
     Eur Respir J. 2022;59.
     PubMed    
     
     
     May 2022
152. NEDER JA, Phillips DB, O'Donnell DE, Dempsey JA, et al
     Excess ventilation and exertional dyspnoea in heart failure and pulmonary hypertension.
     Eur Respir J. 2022 May 26. pii: 13993003.00144-2022.
     PubMed     Abstract available
     
     
     
153. AZZO L, Ali YS, Vaqar S, Dauriat G, et al
     Severe pulmonary hypertension associated with chronic obstructive pulmonary disease Long-term results of a prospective French multicenter cohort.
     Eur Respir J. 2022 May 20. pii: 13993003.02897-2021.
     PubMed     Abstract available
     
     
     
154. BENATTIA A, Bugnet E, Walter-Petrich A, de Margerie-Mellon C, et al
     Long-term outcomes of adult pulmonary Langerhans cell histiocytosis: a prospective cohort.
     Eur Respir J. 2022;59.
     PubMed     Abstract available
     
     
     March 2022
155. TOSHNER M, Church C, Harbaum L, Rhodes C, et al
     Mendelian randomisation and experimental medicine approaches to interleukin-6 as a drug target in pulmonary arterial hypertension.
     Eur Respir J. 2022;59.
     PubMed     Abstract available
     
     
     February 2022
156. OLSSON KM, Richter MJ, Kamp JC, Gall H, et al
     Refined risk stratification in pulmonary arterial hypertension and timing of lung transplantation.
     Eur Respir J. 2022 Feb 10. pii: 13993003.03087-2021.
     PubMed    
     
     

Thank you for your interest in scientific medicine.

AMEDEO Pulmonary Hypertension is free of charge.